{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T23:10:32Z","timestamp":1778195432772,"version":"3.51.4"},"reference-count":28,"publisher":"Georg Thieme Verlag KG","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacopsychiatry"],"abstract":"Abstract<\/jats:title>\n Hypoprolactinemia, an often overlooked condition in psychiatric practice, has\n been suggested to be associated with potential adverse effects on sexual and\n metabolic functions, similar to those reported in hyperprolactinemia.\n Recently, numerous studies have indicated that oral aripiprazole can lead to\n hypoprolactinemia in patients with various psychiatric disorders. However,\n the frequency and severity of hypoprolactinemia in bipolar patients\n receiving a 400-mg dose of once-monthly long-acting injectable aripiprazole\n remain unknown. This study aimed to assess the effects of once-monthly\n long-acting (400 mg) injectable aripiprazole on prolactin levels in patients\n with bipolar disorder.<\/jats:p>\n Fifty patients with bipolar disorder (25 women and 25 men) receiving the\n 400-mg dose of once-monthly long-acting injectable aripiprazole, either as\n monotherapy or in combination with other psychiatric medications, were\n recruited for this study.<\/jats:p>\n Overall, the rate of hypoprolactinemia was 52% among the study participants.\n When stratified by sex, the prevalence was 68% in men and 36% in women. In\n addition, 28% of male patients and 4% of female patients had serum prolactin\n levels below 1 ng\/mL. Mean serum prolactin levels were significantly higher\n in women than in men (z=\u2212\u20093.435, p=0.001). No significant\n correlation was observed between serum prolactin concentrations and age or\n treatment duration in either sex.<\/jats:p>\n Once-monthly injectable aripiprazole treatment in bipolar disorder was\n associated with a relatively high prevalence of hypoprolactinemia in both\n female and male patients. Given emerging evidence of potential metabolic and\n sexual effects of hypoprolactinemia, monitoring prolactin levels may be\n clinically relevant in patients receiving injectable aripiprazole.<\/jats:p>","DOI":"10.1055\/a-2861-6690","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T22:42:21Z","timestamp":1778193741000},"source":"Crossref","is-referenced-by-count":0,"title":["Rates of Hypoprolactinemia in Bipolar Patients Receiving Once-monthly\n Long-acting Injectable Aripiprazole"],"prefix":"10.1055","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4131-2970","authenticated-orcid":false,"given":"Fatma","family":"Simsek","sequence":"additional","affiliation":[{"name":"Ministry of Health Bak\u0131r\u00e7ay University \u00c7i\u011fli Regional Education\n Hospital, Turkey","place":["\u00c7i\u011fli \u0130zmir"],"department":["Department of Psychiatry,"]},{"name":"Institute of Health Sciences, Ege\n University, Turkey","place":["\u0130zmir"],"department":["Department of Neuroscience,"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archgenpsychiatry.2011.12","article-title":"Prevalence and correlates of bipolar spectrum disorder in the world mental\n health survey initiative","volume":"68","author":"K R Merikangas","year":"2011","journal-title":"Arch Gen Psychiatry"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1176\/ps.2008.59.10.1169","article-title":"Trends in use of antipsychotics and mood stabilizers among Medicaid\n beneficiaries with bipolar disorder, 2001\u20132004","volume":"59","author":"C Depp","year":"2008","journal-title":"Psychiatric Serv (Washington, DC)"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/TCRM.S117321","article-title":"Safety, tolerability, and risks associated with first- and second-generation\n antipsychotics: A state-of-the-art clinical review","volume":"13","author":"M Solmi","year":"2017","journal-title":"Ther Clin Risk Manage"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/0269881108098820","article-title":"A UK consensus on the administration of aripiprazole for the treatment of\n mania","volume":"23","author":"K J Aitchison","year":"2009","journal-title":"J Psychopharmacol (Oxford, England)"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.clinthera.2010.01.022","article-title":"Aripiprazole for the maintenance treatment of bipolar I disorder: A review","volume":"32","author":"R S McIntyre","year":"2010","journal-title":"Clin Ther"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust\n pharmacology","volume":"28","author":"D A Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"ref7","first-page":"421","article-title":"The effects of novel and newly approved antipsychotics on serum prolactin\n levels: A comprehensive review","volume":"28","author":"J Peuskens","year":"2014","journal-title":"CNS Drugs"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"168","DOI":"10.4103\/0974-1208.121400","article-title":"Hyperprolactinemia","volume":"6","author":"A Majumdar","year":"2013","journal-title":"J Hum Reprod Sci"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1385\/ENDO:20:1-2:75","article-title":"Hyperprolactinemia in men: Clinical and biochemical features and response to\n treatment","volume":"20","author":"M De Rosa","year":"2003","journal-title":"Endocrine"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/BF00745135","article-title":"Prolactin: A diabetogenic hormone","volume":"13","author":"R Landgraf","year":"1977","journal-title":"Diabetologia"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/JCP.0b013e3182970431","article-title":"Effect of the addition of aripiprazole on hyperprolactinemia associated with\n risperidone long-acting injection","volume":"33","author":"M Ziadi Trives","year":"2013","journal-title":"J Clin Psychopharmacol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.psyneuen.2015.04.011","article-title":"Adjunctive aripiprazole in the treatment of risperidone-induced\n hyperprolactinemia: A randomized, double-blind, placebo-controlled,\n dose-response study","volume":"58","author":"J X Chen","year":"2015","journal-title":"Psychoneuroendocrinology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3371\/CSRP.PRJA.022015","article-title":"Aripiprazole-induced hypoprolactinemia in an adult male with first-episode\n psychosis","volume":"9","author":"A J Propst","year":"2016","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/npr2.12190","article-title":"Hypoprolactinemia and hyperprolactinemia in male schizophrenia patients treated\n with aripiprazole and risperidone and their relationships with testosterone\n levels","volume":"41","author":"M Tasaki","year":"2021","journal-title":"Neuropsychopharmacol Rep"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/JCP.0000000000000527","article-title":"Aripiprazole-associated hypoprolactinemia in the clinical setting","volume":"36","author":"R Sogawa","year":"2016","journal-title":"J Clin Psychopharmacol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1186\/s12888-020-02957-7","article-title":"Abnormally low prolactin levels in schizophrenia patients after switching to\n aripiprazole in a randomized trial: A biomarker for rebound in psychotic\n symptoms?","volume":"20","author":"Y W Jen","year":"2020","journal-title":"Bmc Psychiatry"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s11102-024-01393-0","article-title":"The diagnosis and prevalence of hypoprolactinemia in patients with\n panhypopituitarism and the effects on depression and sexual functions","volume":"27","author":"I Uzun","year":"2024","journal-title":"Pituitary"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.tem.2020.01.004","article-title":"Time for a new perspective on prolactin in metabolism","volume":"31","author":"Y Macotela","year":"2020","journal-title":"Trends Endocrinol Metab"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1111\/j.1743-6109.2008.01206.x","article-title":"Hypoprolactinemia: A new clinical syndrome in patients with sexual\n dysfunction","volume":"6","author":"G Corona","year":"2009","journal-title":"J Sex Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.2337\/dc12-1893","article-title":"Circulating prolactin associates with diabetes and impaired glucose regulation:\n A population-based study","volume":"36","author":"T Wang","year":"2013","journal-title":"Diabetes care"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1093\/humrep\/deu133","article-title":"Prolactin is associated with metabolic risk and cortisol in 1,007 women with\n polycystic ovary syndrome","volume":"29","author":"D Glintborg","year":"2014","journal-title":"Hum Reprod (Oxford, England)"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.jhep.2018.01.035","article-title":"Prolactin improves hepatic steatosis via CD36 pathway","volume":"68","author":"P Zhang","year":"2018","journal-title":"J Hepatol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"e0228648","DOI":"10.1371\/journal.pone.0228648","article-title":"Prolactin response to antipsychotics: An inpatient\n study","volume":"15","author":"L Dehelean","year":"2020","journal-title":"PloS\n One"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0306-4530(02)00128-2","article-title":"Hyperprolactinemia in response to antipsychotic drugs: Characterization across\n comparative clinical trials","volume":"28","author":"B J Kinon","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0306-4530(01)00016-6","article-title":"Effects of olanzapine and haloperidol on serum prolactin levels in male\n schizophrenic patients","volume":"26","author":"E Esel","year":"2001","journal-title":"Psychoneuroendocrinology"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/FTD.0000000000000843","article-title":"Relationship of prolactin concentrations to steady-state plasma concentrations\n of aripiprazole in patients with schizophrenia","volume":"43","author":"M Tasaki","year":"2021","journal-title":"Ther Drug Monit"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/JCP.0b013e3181ee832d","article-title":"Dose-dependent effects of adjunctive treatment with aripiprazole on\n hyperprolactinemia induced by risperidone in female patients with\n schizophrenia","volume":"30","author":"N Yasui-Furukori","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1440-1819.2012.02391.x","article-title":"Prolactin concentrations during aripiprazole treatment in relation to sex,\n plasma drugs concentrations and genetic polymorphisms of dopamine D2\n receptor and cytochrome P450 2D6 in Japanese patients with schizophrenia","volume":"66","author":"G Nagai","year":"2012","journal-title":"Psychiatry Clin Neurosci"}],"container-title":["Pharmacopsychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2861-6690.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T22:42:29Z","timestamp":1778193749000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2861-6690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":28,"URL":"https:\/\/doi.org\/10.1055\/a-2861-6690","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0176-3679","1439-0795"],"issn-type":[{"value":"0176-3679","type":"print"},{"value":"1439-0795","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]}}}